Mycophenolate Mofetil Milpharm (Mycophenolate Mofetil)

The drug selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo synthesis of guanosine nucleotides in lymphocytes. This blockade limits DNA synthesis, preventing proliferation of T‑ and B‑cells and thereby suppressing immune activity.

The exact dosage is individualized and set by the prescribing clinician based on the indication, patient weight, renal function, and other factors. Typical regimens range from 500 mg to 1 g taken twice daily, but the prescriber determines the appropriate schedule.

Mycophenolate Mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy unless no safer alternative exists. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Both agents are immunosuppressants, but Mycophenolate Mofetil more potently inhibits lymphocyte proliferation via IMPDH blockade, offering higher efficacy in preventing transplant rejection. Azathioprine works through purine analog incorporation and may have a different side‑effect profile, including more hepatic toxicity.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Mycophenolate Mofetil Milpharm is taken orally, usually with food or a light snack to reduce gastrointestinal discomfort. The tablets should be swallowed whole with water; they are not intended for crushing, chewing, or dissolving unless specifically instructed by a healthcare professional.

Serious adverse events include bone‑marrow suppression (leading to leukopenia, anemia, or thrombocytopenia), severe infections such as opportunistic fungal or viral illnesses, liver toxicity, and an increased long‑term risk of certain malignancies. Promptly report fever, unusual bruising, jaundice, or persistent gastrointestinal symptoms to a clinician.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid it. It is contraindicated in pregnant women unless absolutely necessary, in individuals with severe uncontrolled infections, and in patients with significant bone‑marrow failure or severe hepatic impairment.